HUTCHMED (China) Limited

NasdaqGS:HCM Stock Report

Market Cap: US$1.8b

HUTCHMED (China) Dividends and Buybacks

Dividend criteria checks 0/6

HUTCHMED (China) does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-0.09%

Buyback Yield

Total Shareholder Yield-0.09%
Future Dividend Yield0%
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

Seeking Alpha • Jan 30

Despite A Promising Future For Hutchmed, We Have Concerns About Development Of The Share Price (Rating Downgrade)

Summary Despite a 32% drop in share price, HCM's oncology treatments show potential for growth, with expected revenue increases driving earnings and share price up. HCM's sale of a 45% stake in Shanghai Hutchison Pharmaceuticals for $608 million will fund internal product development, enhancing its market position. The current share price of $13.56 suggests an attractive valuation with a FWD P/E of 18.1 and an EV/Sales of 2.44. However, concerns over poor performance of the share prices of Li family-controlled companies led us to downgrade HCM from Buy to Hold. Read the full article on Seeking Alpha
Seeking Alpha • Aug 09

Hutchmed Growing Sales By 64% In H1 2024

Summary Share price up nearly 20% since our previous Buy call. Approval of the colon cancer drug FRUZAQLA by the U.S. FDA was a game-changer to their growth in sales. We expect continued growth in sales of oncology products from the approval of FRUZAQLA in the E.U. and Japan. Read the full article on Seeking Alpha
Seeking Alpha • Mar 20

Hutchmed Is Turning Profitable

Summary Hutchmed China is a biopharmaceutical company with a market capitalization of $3 billion. HCM's total revenue doubled to $838 million in 2023, driven by sales of the cancer drug FRUZAQLA. The company delivered a profit of $100.8 million in 2023 and has a strong cash position of over $880 million. FDA approval at the end of last year, and hopefully similar approvals from the EU and Japan will be a gamechanger for HCM. Read the full article on Seeking Alpha
Seeking Alpha • Oct 10

Hutchmed begins dosing in phase 2/3 trial of sovleplenib for red blood cell disorder

Hutchmed (China) (NASDAQ:HCM) said it began dosing in a phase 2/3 trial of sovleplenib in adult patients with warm antibody autoimmune hemolytic anemia in China. Warm autoimmune hemolytic anemia is an autoimmune disorder characterized by premature destruction of healthy red blood cells (hemolysis). The main goal of the phase 2 stage is evaluating the safety and preliminary efficacy of sovleplenib and main goal is the proportion of patients with overall hemoglobin (Hb) response by week 24. If results are positive, phase 3 stage will be started wherein the main goal would be the proportion of patients who achieve a durable Hb response by week 24, the company said in an Oct. 10 press release. The company expects to enroll 110 patients. Hutchmed noted that it currently retains all rights to sovleplenib worldwide. The drug is also being studied in immune thrombocytopenia, indolent non-Hodgkin's lymphoma and multiple subtypes of B-cell malignancies in China, U.S. and Europe.
Seeking Alpha • Aug 09

Hutchmed, Inmagene begin dosing in phase 1 trial of potential autoimmune disease drug IMG-004

Hutchmed (China) (NASDAQ:HCM) and Inmagene Biopharmaceuticals said the first person based in the U.S. was dosed in a global phase 1 trial of IMG-004. Inmagene is developing IMG-004 to potentially treat immunological diseases. The study aims to evaluate IMG-004's safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy people. Inmagene's Chairman and CEO Jonathan Wang said that  IMG-004 was the second drug candidate under the collaboration with Hutchmed which the company successfully advanced into clinical studies this year. "Inmagene also expects to submit another investigational new drug (IND) application for a third novel drug candidate in 2022," Wang noted.
Seeking Alpha • Aug 01

Hutchmed begins dosing in mid-stage study of tazemetostat in blood cancer subtype

Hutchmed (China) (NASDAQ:HCM) said it began dosing in a phase 2 bridging study of tazemetostat in China to treat patients with relapsed/refractory follicular lymphoma (R/R FL). Tazemetostat is developed by Epizyme (NASDAQ:EPZM) and Hutchmed has an agreement with the Cambridge, Mass.-based company to develop and sell the drug in China, Hong Kong, Macau and Taiwan. Epizyme is in the process of being acquired by France's Ipsen. Hutchmed said that the main goal of the study is to evaluate the efficacy of tazemetostat to treat patients with R/R FL who have mutations in the EZH2 gene (Cohort 1). Meanwhile, the secondary goals is to check efficacy of the drug in treating patients with R/R FL who have EZH2 wild-type (Cohort 2) and to evaluate safety. Follicular lymphoma occurs when the body develops abnormal B lymphocytes, type of white blood cells.

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if HCM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HCM's dividend payments have been increasing.

Dividend Yield vs Market

HUTCHMED (China) Dividend Yield vs Market
How does HCM dividend yield compare to the market?
SegmentDividend Yield
Company (HCM)n/a
Market Bottom 25% (US)1.4%
Market Top 25% (US)4.2%
Industry Average (Pharmaceuticals)2.0%
Analyst forecast (HCM) (up to 3 years)0%

Notable Dividend: Unable to evaluate HCM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate HCM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate HCM's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as HCM has not reported any payouts.

Discover strong dividend paying companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/26 21:59
End of Day Share Price 2026/06/26 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

HUTCHMED (China) Limited is covered by 53 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alec StranahanBofA Global Research
John NewmanCanaccord Genuity
Adam McCarterCavendish